Drug Profile
EBV specific TCR redirected T-cell therapy - Lion TCR
Alternative Names: Epstein Barr virus related nasopharyngeal carcinoma- Lion TCR; LT-C50Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Lion TCR
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Nasopharyngeal cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Nasopharyngeal-cancer in Singapore (Parenteral)
- 11 Feb 2022 Preclinical development is ongoing in Singapore (Lion TCR pipeline, February 2022)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Nasopharyngeal-cancer in Singapore (Parenteral)